Gain Therapeutics, Inc. (GANX) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Gain Therapeutics reported revenue of $0. Net income was -$20.2M, or -$0.61 per diluted share. Operating activities generated -$18.5M of cash, leaving -$18.5M of free cash flow. At fiscal year end, Gain Therapeutics held $22.8M in total assets against $4.3M in total liabilities, including $20.8M of cash and equivalents.
Open the full interactive Gain Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Gain Therapeutics Key Stats
| Share Price | $1.41 |
|---|---|
| Market Cap | $60.5M |
| 52-Week Range | $1.41 – $4.18 |
| Shares Outstanding | 42.9 million (basic, 2026 Q2) |
Gain Therapeutics Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $164,994 | $140,108 | $55,180 | $0 | $0 |
| Operating Income | -$13.8M | -$17.8M | -$22.3M | -$20.4M | -$18.7M |
| Pre-Tax Income | -$13.9M | -$17.5M | -$22.2M | -$19.9M | -$19.3M |
| Income Tax | $4,008 | $92,976 | $79,275 | $536,815 | $861,118 |
| Net Income | -$13.9M | -$17.6M | -$22.3M | -$20.4M | -$20.2M |
| Diluted EPS | -$1.37 | -$1.48 | -$1.71 | -$0.89 | -$0.61 |
Gain Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$5.3M | -$4.5M | -$5.6M | -$4.7M |
| Diluted EPS | -$0.15 | -$0.14 | -$0.13 | -$0.11 |
Gain Therapeutics Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $36.9M | $7.3M | $11.8M | $10.4M | $20.8M |
| Current Assets | $37.7M | $21.1M | $17.8M | $11.6M | $22.2M |
| Total Assets | $39.0M | $24.1M | $18.6M | $12.1M | $22.8M |
| Current Liabilities | $2.6M | $4.1M | $4.9M | $3.9M | $3.4M |
| Total Long-Term Debt | $694,294 | $603,393 | $567,850 | $438,504 | $400,953 |
| Total Liabilities | $4.2M | $5.2M | $6.0M | $4.8M | $4.3M |
| Shareholders' Equity | $34.8M | $18.9M | $12.6M | $7.3M | $18.6M |
Gain Therapeutics Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$12.4M | -$14.7M | -$18.9M | -$18.9M | -$18.5M |
| Cash From Investing | -$94,212 | -$14.8M | $10.2M | $5.0M | — |
| Cash From Financing | $41.8M | -$78,774 | $12.6M | $13.0M | $28.4M |
| Free Cash Flow | -$12.5M | -$14.8M | -$18.9M | -$18.9M | -$18.5M |
Figures from Gain Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Gain Therapeutics financials page for every line item.
Gain Therapeutics Company Profile
| Ticker | GANX |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Bethesda, Maryland |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001819411 |
Frequently Asked Questions
What was Gain Therapeutics' revenue in fiscal 2025?
Gain Therapeutics (GANX) reported revenue of $0 for fiscal 2025.
What is Gain Therapeutics' annual revenue history?
Gain Therapeutics' annual revenue by fiscal year: 2021: $164,994; 2022: $140,108; 2023: $55,180; 2024: $0; 2025: $0.
What was Gain Therapeutics' net income in fiscal 2025?
Gain Therapeutics reported net income of -$20.2M for fiscal 2025.
What was Gain Therapeutics' earnings per share (EPS) in fiscal 2025?
Gain Therapeutics' diluted EPS was -$0.61 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Gain Therapeutics generate in fiscal 2025?
Gain Therapeutics generated -$18.5M of free cash flow in fiscal 2025.
What was Gain Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Gain Therapeutics reported revenue of $0.
How much debt does Gain Therapeutics have?
Gain Therapeutics reported $400,953 of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Gain Therapeutics are outstanding?
Gain Therapeutics reported a weighted average of 42.9 million basic shares outstanding in 2026 Q2.
What is Gain Therapeutics' market cap?
Based on its latest closing price, Gain Therapeutics (GANX) has a market capitalization of about $60.5M.
When does Gain Therapeutics' fiscal year end?
Gain Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Gain Therapeutics headquartered?
Gain Therapeutics lists its business address in Bethesda, Maryland in its SEC filings.